These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32940991)

  • 1. [Pharmaceutical pricing; what is reasonable?].
    Versteegh MM
    Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel perspective on pharmaceutical R&D costs: opportunities for reductions.
    van der Schans S; De Loos F; Boersma C; Postma MJ; Büller H
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):167-175. PubMed ID: 34595997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.
    Thielen FW; Heine RJSD; Berg SVD; Ham RMTT; Groot CAU
    Cytotherapy; 2022 Dec; 24(12):1245-1258. PubMed ID: 36216697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.
    Franzen N; Ziegler A; Romagnoli G; Retèl VP; Offerman TJS; van Harten WH
    Cancer Res Commun; 2022 Jan; 2(1):49-57. PubMed ID: 36860697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
    Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
    Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical drug development: high drug prices and the hidden role of public funding.
    Annett S
    Biol Futur; 2021 Jun; 72(2):129-138. PubMed ID: 34554467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
    Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
    Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy.
    Shibata S; Fukumoto D; Suzuki T; Ozaki K
    Ther Innov Regul Sci; 2020 May; 54(3):544-551. PubMed ID: 33301139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate.
    Roediger A; Schönbächler G; Brand H
    Public Health; 2024 Jun; 231():148-153. PubMed ID: 38692089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.
    Hasan SS; Kow CS; Dawoud D; Mohamed O; Baines D; Babar ZU
    Value Health Reg Issues; 2019 May; 18():18-23. PubMed ID: 30414506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical pricing in Europe: time to take the right direction.
    Garattini L; Finazzi B; Mannucci PM
    Intern Emerg Med; 2022 Jun; 17(4):945-948. PubMed ID: 35303264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab.
    Heine RJSD; Thielen FW; Mathijssen RHJ; van Leeuwen RWF; Franken MG; Uyl-de Groot CA
    PLoS One; 2024; 19(2):e0293264. PubMed ID: 38300937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.